Stockreport

Amylyx Pharmaceuticals Announces Completion of Enrollment in Pivotal Phase 3 LUCIDITY Clinical Trial of Avexitide in Post-Bariatric Hypoglycemia

Amylyx Pharmaceuticals, Inc.  (AMLX) 
PDF Last participant has been randomized and dosed in the LUCIDITY trial of avexitide; LUCIDITY enrolled a total of 78 participantsTopline data readout on track; anticipated [Read more]